Rep. Michael T. McCaul sold Neurocrine Biosciences (NBIX)
Rep. Michael T. McCaul (R-TX-10) · $15K–$50K · traded May 2, 2023
- Transaction
- Sold
- Amount
- $15K–$50K
- Owner
- Spouse
- Traded
- May 2, 2023
- Disclosed
- Jun 22, 2023
- Days to disclose
- 51 (after the 45-day deadline)
- Asset type
- Stock
- As filed
- Neurocrine Biosciences Inc
- Industry
- Biotechnology · Healthcare
Other trades in this filing
All of McCaul's trades →- Jun 22, 2023$1K–$15K
$1K–$15K · Traded May 31, 2023 · disclosed Jun 22, 2023 · Spouse
- Jun 22, 2023$1K–$15K
$1K–$15K · Traded May 31, 2023 · disclosed Jun 22, 2023
- Jun 22, 2023$1K–$15K
$1K–$15K · Traded May 31, 2023 · disclosed Jun 22, 2023 · Spouse
- Jun 22, 2023$1K–$15K
$1K–$15K · Traded May 31, 2023 · disclosed Jun 22, 2023
- Jun 22, 2023$15K–$50K
$15K–$50K · Traded May 30, 2023 · disclosed Jun 22, 2023
- Jun 22, 2023$15K–$50K
$15K–$50K · Traded May 30, 2023 · disclosed Jun 22, 2023 · Spouse
- Jun 22, 2023$1K–$15K
$1K–$15K · Traded May 30, 2023 · disclosed Jun 22, 2023 · Spouse
- Jun 22, 2023$15K–$50K
Sold Automatic Data Processing ADP
$15K–$50K · Traded May 30, 2023 · disclosed Jun 22, 2023
- Jun 22, 2023$15K–$50K
Sold Automatic Data Processing ADP
$15K–$50K · Traded May 30, 2023 · disclosed Jun 22, 2023 · Spouse
- Jun 22, 2023$1K–$15K
$1K–$15K · Traded May 30, 2023 · disclosed Jun 22, 2023
- Jun 22, 2023$15K–$50K
Bought National Fuel Gas Company NFG
$15K–$50K · Traded May 26, 2023 · disclosed Jun 22, 2023 · Spouse
- Jun 22, 2023$15K–$50K
$15K–$50K · Traded May 26, 2023 · disclosed Jun 22, 2023 · Spouse
- Jun 22, 2023$1K–$15K
$1K–$15K · Traded May 26, 2023 · disclosed Jun 22, 2023
- Jun 22, 2023$1K–$15K
Bought National Fuel Gas Company NFG
$1K–$15K · Traded May 26, 2023 · disclosed Jun 22, 2023
- Jun 22, 2023$1K–$15K
Bought National Fuel Gas Company NFG
$1K–$15K · Traded May 25, 2023 · disclosed Jun 22, 2023
- Jun 22, 2023$1K–$15K
$1K–$15K · Traded May 25, 2023 · disclosed Jun 22, 2023 · Spouse
- Jun 22, 2023$1K–$15K
$1K–$15K · Traded May 25, 2023 · disclosed Jun 22, 2023
- Jun 22, 2023$15K–$50K
Bought National Fuel Gas Company NFG
$15K–$50K · Traded May 25, 2023 · disclosed Jun 22, 2023 · Spouse
- Jun 22, 2023$50K–$100K
$50K–$100K · Traded May 25, 2023 · disclosed Jun 22, 2023 · Spouse
- Jun 22, 2023$50K–$100K
Bought FORT BEND INDEPENDENT SCHOOL DISTRICT
$50K–$100K · Traded May 25, 2023 · disclosed Jun 22, 2023 · Spouse
Recent Congress trades in NBIX
- Aug 13, 2025$1K–$15K
Rep. Lisa C. McClain (R-MI-9)
Sold (partial) Neurocrine Biosciences NBIX
$1K–$15K · Traded Jun 17, 2025 · disclosed Aug 13, 2025 · Spouse · filed 57 days later
- Aug 13, 2025$1K–$15K
Rep. Lisa C. McClain (R-MI-9)
Bought Neurocrine Biosciences NBIX
$1K–$15K · Traded Jun 11, 2025 · disclosed Aug 13, 2025 · Spouse · filed 63 days later
- Jun 22, 2023$15K–$50K
Rep. Michael T. McCaul (R-TX-10)
Sold Neurocrine Biosciences NBIX
$15K–$50K · Traded May 2, 2023 · disclosed Jun 22, 2023 · filed 51 days later
Company context for NBIX
Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.
NBIX: third_quarter 2026 lobbying report
IRA, prescription drug pricing, payment reform, innovation telehealth, mental health, prescription drug pricing, payment reform federal budget issues
Public: Oct 20, 2026, 3:14 PM EDTOriginal source ↗NBIX: third_quarter 2026 lobbying report
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy
Public: Oct 20, 2026, 2:20 PM EDTOriginal source ↗NBIX: third_quarter 2026 lobbying report
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432
Public: Oct 20, 2026, 12:10 PM EDTOriginal source ↗
From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.